Evaluating a Digital Intervention for Overactive Bladder
Evaluating a Digital Intervention for Overactive Bladder: Protocol for a Single-arm, Multisite Pilot Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, D01 P5W9
- The Rotunda Hospital
-
Dublin, Ireland, D02 YH21
- The National Maternity Hospital
-
Galway, Ireland, H91 YR71
- Galway University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- On waiting list for Urogynaecologist at participating hospital
- Referred for Overactive bladder from GP
- Symptoms of Overactive bladder to include at least one of the following: urgency of urination, frequency of urination or urge incontinence.
- Female
- 18 years or older
- Own a smartphone
Exclusion Criteria:
- Active/Recurrent urinary tract infection
- Urinary retention
- Bladder Pain Syndrome/ interstitial cystitis
- Pelvic/gynae cancer
- Pregnant
- Dementia
- Kidney problems
- Stroke
- Have/had a neuro-stimulation implant for treatment of OAB
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: NUIG OAB App
Digital behaviour change intervention.
Software-delivered intervention including best-practice behavioural therapy, and evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
|
An interactive software-delivered 8-week intervention accessed through the patients' mobile device.
It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Module (ICIQ-OABqol)
Time Frame: baseline and week 8
|
Change from baseline patient-reported overactive bladder related quality of life at week 8. Minimum score 25, maximum score 160.
Greater values indicating increased impact on quality of life
|
baseline and week 8
|
|
Change in International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB)
Time Frame: baseline and week 8
|
Change from baseline patient-reported overactive bladder symptoms at week 8. Minimum score 0, maximum score 16.
Greater values indicate increased symptom severity.
|
baseline and week 8
|
|
Change in Digital Bladder Diary frequency of urination
Time Frame: baseline & week 8
|
Change from baseline frequency of urination at week 8. Frequency of urination measured in-app, in real-time as number of urinations per day logged by user for 3 days at baseline and 3 days in week 8. |
baseline & week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Programme adherence
Time Frame: data collected throughout the 8 week intervention.
|
Total number of seconds spent on app from day 1 of week 1 to day 7 of week 8.
Total number of times app accessed between day 1 of week 1 and day 7 of week 8.
Total number of in-app 'challenges' completed throughout the 8 week intervention.
|
data collected throughout the 8 week intervention.
|
|
Mobile Applications Rating Scale, user version (MARSu)
Time Frame: week 4
|
User reported ratings of app quality based on Engagement, Functionality, Aesthetics, and Information.
Minimum score 20, maximum score 100.
Greater values indicate higher app quality.
|
week 4
|
|
Patient Global impression of improvement
Time Frame: week 8
|
One item questionnaire with Likert scale of 1 to 7. Greater values indicate disimproved condion.
|
week 8
|
|
Change in International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Module (ICIQ-OABqol)
Time Frame: baseline and week 4
|
Change from baseline patient-reported overactive bladder related quality of life at week 4. Minimum score 25, maximum score 160.
Greater values indicate increased impact on quality of life.
|
baseline and week 4
|
|
Change in International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB)
Time Frame: baseline and week 4
|
Change from baseline patient-reported overactive bladder symptoms at week 4. Minimum score 0, maximum score 16.
Greater values indicate increased symptom severity.
|
baseline and week 4
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Brendan Staunton, National University of Ireland, Galway
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CF20201467I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.